Anti-COVID-19 Nasal Spray Gets Interim Approval in Israel


As nations around the globe race to find different solutions to prevent the further spread of the dreaded COVID-19 virus, Israel gave interim approval for the sale of Canadian-based biotech company SaNOtize Research and Development’s Nitric Oxide Nasal Spray (NONS) branded as Enovid.

SaNOtize developed and patented the platform technology that allows for the topical delivery of Nitric Oxide (the formula written as NO) for treating a variety of bacterial, fungal, and viral diseases. Utilizing the unique antimicrobial and immunomodulating properties of NO to treat both dermatologic and respiratory diseases, the production of this nose spray that claims to kill 99.9% of viruses within 2 minutes started in Israel last month. It should be important to say it again, these are only claims.

But let's say these claims have some merit. Could this be a solution to countries that are lagging behind the inoculation of their citizens due to supply problems related to the COVID-19 vaccines?

Experts say that the formulation of NO for human use can kill viruses in the upper airways, effectively preventing them from incubating and further spreading to the lungs.

On its website, SaNOtize listed the following mechanisms of action for their anti-viral nasal spray: Antibacterial, Antiviral, In the Cell, Antifungal, Anti-inflammatory, Increase Blood Flow, and Enhanced Wound Healing.

I reached out to SaNOtize over the weekend and the company’s CEO and Co-founder confirmed that they are currently working on regulatory approval in the Philippines.

“We are working to identify the right partners that can help us get through regulatory approvals in different countries and we have a few contacts in the Philippines. We are in contact with WHO on potential adding our treatment to their testing but they do not have a prevention trial going,” according to Israeli-Canadian scientist Dr. Gilly Regev, CEO & Co-founder of SaNOtize Research and Development Corp.

In the United Kingdom, the results of recent clinical trials show that NONS is indeed effective as an antiviral treatment to prevent the transmission of COVID-19. The product shortens the virus’ course, and reduces the severity of symptoms and damage for those already infected.